A detailed history of Dark Forest Capital Management LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Dark Forest Capital Management LP holds 14,894 shares of RCUS stock, worth $239,495. This represents 0.03% of its overall portfolio holdings.

Number of Shares
14,894
Holding current value
$239,495
% of portfolio
0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $203,898 - $268,240
14,894 New
14,894 $227,000
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $527,799 - $718,206
35,590 New
35,590 $671,000
Q3 2023

Nov 13, 2023

BUY
$17.62 - $23.54 $673,506 - $899,792
38,224 New
38,224 $686,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $667,438 - $1.46 Million
-38,737 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$28.92 - $41.83 $1.12 Million - $1.61 Million
38,588 Added 25897.99%
38,737 $1.22 Million
Q4 2021

Feb 11, 2022

BUY
$31.38 - $48.47 $4,675 - $7,222
149 New
149 $6,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.16B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Dark Forest Capital Management LP Portfolio

Follow Dark Forest Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dark Forest Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Dark Forest Capital Management LP with notifications on news.